Humacyte, Inc.
For the period ended Sep 30, 2025. Filed Nov 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 12, 2025
HUMA$0.59+29.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets (unaudited)
Condensed Consolidated Balance Sheets
(in thousands except for share and per share amounts)
| September 30,2025 | December 31,2024 | |
|---|---|---|
| ASSETS | ||
| Current assets | ||
| Cash and cash equivalents | $19,488 | $44,937 |
| Inventory | 18,418 | — |
| Accounts receivable | 1,078 | 180 |
| Prepaid expenses and other current assets | 2,367 | 2,742 |
| Total current assets | 41,351 | 47,859 |
| Restricted cash | 209 | 50,209 |
| Property and equipment, net | 19,857 | 23,063 |
| Finance lease right-of-use assets, net | 29,420 | 15,490 |
| Other long-term assets | 672 | 1,251 |
| Total assets | $91,509 | $137,872 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | ||
| Current liabilities | ||
| Accounts payable | $9,575 | $4,490 |
| Accrued expenses | 10,264 | 11,424 |
| Finance lease obligation, current portion | 2,670 | 2,917 |
| Revenue interest liability, current portion | 3,072 | 885 |
| Other current liabilities | — | 238 |
| Total current liabilities | 25,581 | 19,954 |
| Revenue interest liability, net of current portion | 17,674 | 63,354 |
| Contingent Earnout Liability | 21,807 | 70,961 |
| Finance lease obligation, net of current portion | 27,155 | 13,620 |
| Common stock warrant liabilities | 3,234 | 19,254 |
| Contingent derivative liability | 289 | 2,415 |
| Other long-term liabilities | 520 | 983 |
| Total liabilities | 96,260 | 190,541 |
| Commitments and contingencies (Note 12) | ||
| Stockholders’ equity (deficit) | ||
| Preferred stock, $0.0001 par value; 20,000,000 shares designated as of September 30, 2025 and December 31, 2024; 0 shares issued and outstanding as of September 30, 2025 and December 31, 2024 | — | — |
| Common stock, $0.0001 par value; 350,000,000 and 250,000,000 shares authorized as of September 30, 2025 and December 31, 2024, respectively; 158,835,303 and 130,027,509 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively | 16 | 13 |
| Additional paid-in capital | 697,277 | 633,333 |
| Accumulated deficit | (702,044) | (686,015) |
| Total stockholders’ equity (deficit) | (4,751) | (52,669) |
| Total liabilities and stockholders’ equity (deficit) | $91,509 | $137,872 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.